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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

DATA, POLICIES AND CONFLICTS OF INTEREST IN RESEARCH
JEREMY SUGARMAN, MD, MPH, MA*
I. INTRODUCTION
In the wake of the death of Jesse Gelsinger in a gene transfer
experiment at the University of Pennsylvania, substantial attention has
focused on financial conflicts of interests (COIs) in research.1 Numerous
groups have promulgated policies and guidance regarding these COIs,
which typically involve a series of procedural steps to assess and manage
financial interests in research.2 While a review of such policies is beyond the
scope of this paper, they tend to share a common feature of considering
disclosing financial interests to potential research participants. However, at
the time many policies were crafted, little was known or specified about the
process of disclosure, including who should disclose, what should be
disclosed, when it should be disclosed, where it should be disclosed, how it
should be disclosed, and what effects disclosure might have on the potential
research participant and the research enterprise. For example, would
disclosure affect willingness to participate in research? Would it affect trust?
Nevertheless, the answers to such questions seem critical to understanding
how such policies might be implemented, their potential effects, and their
utility. The Conflict of Interest Notification Study (COINS) set out to provide
systematic data about these and related issues.
COINS was a multi-year project funded by the National Institutes of
Health and included a multidisciplinary team of scholars based at Duke
University, Johns Hopkins University, and Wake Forest University.3 At each
stage of the project, COINS consulted an advisory panel, which consisted of
individuals with expertise in clinical trials, conflicts of interest, ethics, and the
* Berman Institute of Bioethics, Department of Medicine, and Department of Health Policy and
Management, Johns Hopkins University, Baltimore, Maryland.
1. See Robert Fretwell Wilson, The Death of Jesse Gelsinger: New Evidence of the
Influence of Money and Prestige in Human Research, 36 AM. J.L. & MED. 295, 295-96
(2010).
2. See id. at 322.
3. Press Release, Johns Hopkins Medicine, Disclosing Financial Conflicts of Interest to
Research Participants May Not Be Enough (Aug. 26, 2009), available at http://www.hopkins
medicine.org/news/media/releases/Disclosing_Financial_Conflicts_of_Interest_to_Research_
Participants_May_Not_Be_Enough.
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law; the panel had representatives from academia and industry.4 In this
paper, I review briefly what we learned over the course of the project and
then discuss some barriers for gathering data about COIs that would
enhance current understanding about these issues.
II. WHAT WE LEARNED
COINS had several stages: 1) reviewing COI of policies; 2) obtaining
stakeholder input; 3) developing model disclosure language and measures
of trust; 4) evaluating the effects of disclosure; 5) considering the goals of
disclosure; and 6) assessing COI management. I will discuss each of these
in turn.
A.

COI Policies

At the time of our review, the policies of nearly half of academic medical
centers in the United States that had an Institutional Review Board (IRB)
mentioned the possibility of disclosing financial conflicts of interest to
potential research participants.5 In addition, more than half of those that
mentioned disclosure included specific language that could be used.6
However, there was substantial variability concerning the content of such
disclosures.7
We subsequently compared the results of our policy review with the
findings from interviews with IRB and Conflict of Interest Committee (COIC)
officials (described below).8 The interviews revealed a range of practices
regarding the management of COIs that was broader than those suggested
in written policies.9 Further, COI and IRB officials interpreted and
understood policies regarding COI differently.10

4. Kevin P. Weinfurt et al., Developing Model Language for Disclosing Financial
Interests to Potential Clinical Research Participants, IRB: ETHICS & HUMAN RES., Jan.-Feb. 2007,
at 1, 2 [hereinafter Weinfurt et al., Developing Model Language].
5. Kevin P. Weinfurt et al., Policies of Academic Medical Centers for Disclosing Financial
Conflicts of Interest to Potential Research Participants, 81 ACAD. MED. 113, 114 (2006).
6. Id.
7. Id. at 115.
8. Michaela A. Dinan et al., Comparison of Conflict of Interest Policies and Reported
Practices in Academic Medical Centers in the United States, 13 ACCOUNTABILITY RES. 325, 328
(2006).
9. Id. at 333 tbl.4.
10. Id. at 340.
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Stakeholder Input

Given their relevant interests in COIs in research, we sought data from
three stakeholder groups: 1) potential research participants; 2) institutional
officials and investigators; and 3) study coordinators.
First, we conducted a series of focus groups with potential research
subjects.11 In these focus groups “we found that many participants want to
know about financial interests in research, whether or not they report that
such knowledge would affect their decision to participate. However, we
documented great variability in participants’ desire and aptitude to
understand the nature and implications of financial interests in clinical
research.”12 In addition, in contrast to most commentators on COI, some
participants thought that financial interests in research might be beneficial.13
Second, we conducted interviews with selected IRB and COIC officials
and investigators from academic medical centers, independent hospitals,
and non-affiliated research entities.14 The interviewees revealed a variety of
approaches to disclosing financial interests in research as well as differing
views on what is appropriate in this regard.15
Third, we surveyed study coordinators who are often charged with
actually disclosing financial interests to potential research participants.16
Based on the results, we concluded “that making information about
financial interests in research readily available to clinical research
coordinators, as well as providing education and training, would facilitate
the disclosure of financial interests to potential research participants during
the informed consent process.”17
C. Model Disclosure Language and Measuring Trust
Using a multi-staged process, we developed model disclosure language
that might be used to describe a variety of financial interests to potential
research participants.18 In crafting this language, we relied upon existing
11. Kevin P. Weinfurt et al., Views of Potential Research Participants on Financial
Conflicts of Interest: Barriers and Opportunities for Effective Disclosure, 21 J. GEN. INTERNAL
MED. 901, 901 (2006).
12. Id. at 904.
13. Id. at 903.
14. Kevin P. Weinfurt et al., Disclosing Conflicts of Interest in Clinical Research: Views of
Institutional Review Boards, Conflict of Interest Committees, and Investigators, 34 J.L. MED. &
ETHICS 581, 582 (2006) [hereinafter Weinfurt et al., Disclosing Conflicts of Interest].
15. Id. at 583, 584 tbl.1.
16. Joëlle Y. Friedman et al., Perspectives of Clinical Research Coordinators on
Disclosing Financial Conflicts of Interest to Potential Research Participants, 4 CLINICAL TRIALS
272, 273 (2007).
17. Id. at 278.
18. Weinfurt et al., Developing Model Language, supra note 4, at 3.
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literature, expert review, reactions to draft language during focus groups
with potential research participants, and cognitive pre-testing with potential
research participants.19
As mentioned above, based on the uncertainties that disclosure of
financial interests in research might have on trust, we wanted to be able to
accurately measure this important outcome. Since there was no readily
available measure of trust in medical researchers, we developed and tested
appropriate scales.20
D. Effects of Disclosure
Using the empirically-derived model language, we tested the effects of
disclosure in two separate studies. The first involved an internet-based survey
of patients with asthma or diabetes.21 Participants were given a description
of a hypothetical study of a drug aimed at improving their disease.22 All of
the information about the studies was identical, except that participants were
randomly assigned to one of five types of financial interest disclosures.23 In
most cases, financial interests had no significant differences on willingness
to participate in the research and trust.24 However, “[r]espondents
consistently viewed a researcher owning equity less favorably than a
researcher receiving per capita payments.”25
Although the internet-based study provided powerful data because of its
size, it did not have great verisimilitude to actual clinical research practices.
Therefore, we conducted a phone-based study involving cardiology
patients.26 In this study, patients received a letter from their cardiologist
asking if they would be willing to participate in our survey.27 Interested
patients contacted our research team and were then sent a consent
document for a hypothetical study involving a medication to improve
cardiac disease.28 Similar to the internet study, all information about the

19. Id. at 2 tbl.1.
20. See Mark A. Hall et al., Measuring Trust in Medical Researchers, 44 MED. CARE
1048, 1050-51 (2006).
21. Kevin P. Weinfurt et al., Effects of Disclosing Financial Interests on Attitudes Toward
Clinical Research, 23 J. GEN. INTERNAL MED. 860, 860-61, 865 (2008) [hereinafter Weinfurt
et al., Effects of Disclosing on Attitudes].
22. Id. at 861.
23. Id.
24. Id. at 862, 865.
25. Id. at 863.
26. Kevin P. Weinfurt et al., Effects of Disclosing Financial Interests on Participation in
Medical Research: A Randomized Vignette Trial, 156 AM. HEART J. 689, 689 (2008)
[hereinafter Weinfurt et al., Effects of Disclosing on Participation].
27. Id.
28. Id.
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hypothetical study was the same except that participants were randomly
assigned to one of three disclosure conditions (per capita payments, equity
interest, or no disclosure).29 After the patient had received the material, the
research assistant would review the consent document with them over the
phone and ask about their willingness to participate in the hypothetical trial
and measure trust.30 The results were remarkably consistent with those of the
internet study.31
E.

Goals of Disclosure

In aggregate, the data we accumulated suggested that there was a lack
of clarity about the goals of disclosing financial interests in research and that
there can be barriers to meeting them. Such goals include: promoting
informed decision making; respecting participants’ perceived right to know;
establishing or maintaining trust; minimizing risk of legal liability; deterring
troubling financial relationships; and protecting participants’ welfare.32 In
the end, disclosure alone seems to be an incomplete management tool for
financial interests in research.33 Rather, it is best considered an important
component of management strategies.
F.

COI Management

Given the importance of management strategies, COINS conducted
some preliminary research to begin to describe some of the structural issues
that may be relevant to COIs and the management approaches being used
in different settings. Based on a small number of interviews with staff at
health care organizations across the nation, it became apparent that the
way investigators are compensated in clinical research settings outside of
academic medical centers, such as community hospitals, may affect whether
financial interests indeed pose a conflict.34 In addition, a variety of different
methods are used to address financial interests in research. A survey of
institutions that participate in high-profile clinical research confirmed that
different approaches to oversight are used.35 Finally, since per capita
29. Id. at 690.
30. Id.
31. Compare Weinfurt et al., Effects of Disclosing on Participation, supra note 26, at
691, with Weinfurt et al., Effects of Disclosing on Attitudes, supra note 21, at 862.
32. Kevin P. Weinfurt et al., Disclosure of Financial Relationships to Participants in
Clinical Research, 361 NEW ENG. J. MED. 916, 917 tbl.1 (2009).
33. See id. at 920.
34. Mark A. Hall et al., Community Hospital Oversight of Clinical Investigators’ Financial
Relationships, IRB: ETHICS & HUMAN RES., Jan.-Feb. 2009, at 9-10.
35. Kevin P. Weinfurt et al., Oversight of Financial Conflicts of Interest in Commercially
Sponsored Research in Academic and Nonacademic Settings, 25 J. GEN. INTERNAL MED. 460,
463 (2010).
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payments in clinical research are commonplace, we explored some of the
issues related to assessing the acceptability of particular payments. Clearly,
more attention should focus on how per capita payments for research are
determined and used in order to assess more accurately whether they pose
a COI.36
III. BARRIERS TO GATHERING DATA ABOUT COIS
While the COINS team was able to gather systematic data concerning
the disclosure of financial interests to potential research participants, barriers
were encountered with respect to two important related areas: nesting a
study of different disclosures in the context of actual clinical research and
assessing non-financial conflicts of interest.
A.

Nesting a Study in an Actual Clinical Trial

As COINS was being developed, we envisioned conducting a
randomized study of different approaches to disclosing financial interests in
the context of an actual clinical trial. This method would be best suited to
provide strong evidence regarding whether the empirically developed
disclosure language in COINS performed better than existing language.
While we had substantial experience nesting trials related to informed
consent in actual research settings,37 the proposed study proved to be
especially challenging for a variety of reasons. First, in order to conduct a
nested study about the disclosure of financial interests in research, we
needed to identify a large enough study to have statistical power to compare
different approaches to disclosure. Realistically, this required identifying a
trial being conducted at several institutions. However, because individual
IRBs and COICs may use different templates for disclosure,38 it would be
difficult to make a meaningful comparison. Moreover, the necessity for
multiple reviews would likely undermine our ability to field the trial. A
practical and ethically acceptable alternative was to identify a multiinstitutional study that was being overseen by an independent IRB that also
manages financial interests in research. As it turns out, following a meeting
with its members, a prominent independent IRB was willing to collaborate
on a trial, testing its standard disclosure language against the COINS
empirically derived language. Next, we had to identify a trial in which actual
financial interests were in play, necessitating that we identify an industrysponsored trial. Accordingly, we discussed the possibility of collaborating
36. Mark A. Hall et al., Per Capita Payments in Clinical Trials: Reasonable Costs Versus
Bounty Hunting, 85 ACAD. MED. 1554, 1554-56 (2010).
37. See, e.g., Philip W. Lavori et al., Quality Assurance Questionnaire for Professionals
Fails to Improve the Quality of Informed Consent, 4 CLINICAL TRIALS 638, 638-39 (2007).
38. Weinfurt et al., Disclosing Conflicts of Interest, supra note 14, at 582, 584 tbl.1.
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with several different sponsors. Although there was substantial interest in the
research question, ultimately industry sponsors elected not to collaborate,
tending to cite their corporate fiduciary obligations. Simply put, even though
financial interests are part of their work, drawing attention to the issue of
COI was seen to be risky. Thus, without willing collaborators, we had to
abandon the possibility of testing alternative disclosure language in the
context of actual research, relying instead on the hypothetical approaches
described earlier.
B.

Non-Financial Conflicts of Interest

Although substantial attention has focused on financial COIs, anecdotal
evidence suggests that non-financial conflicts may pose substantial risks to
the integrity of the research enterprise. For instance, James Wilson, who was
the principal investigator in the trial in which Jesse Gelsinger was enrolled,
describes such conflicts.39 However, given the lack of systematic data
regarding the nature of non-financial and their potential relationship to
research integrity and safety, a subset of the COINS team and others set out
to explore this issue. In crafting the proposal, the team recognized that
unlike financial interests that are easily quantified, non-financial conflicts
would likely be difficult to define and understand. Accordingly, the proposal
included the use of qualitative methods at the outset, such as using focus
groups and key-informant interviews, to help develop an online survey.
Unfortunately, the proposal for this work was not funded. Perhaps this was
related to the difficulty that can be encountered in getting qualitative
research funded or that the topic itself was threatening.40 Regardless, this
important work remains undone.
IV. CONCLUDING COMMENTS
Despite the barriers encountered in obtaining some information about
COIs in research, it has been possible to build a rich data set concerning
the disclosure of financial interests to potential research participants. These
data are well situated to enhance disclosure through informed policies and
practices. In addition, these data challenge some of our assumptions and
conceptual understandings about financial interests in research. Future
research should be directed at examining and testing management
strategies for financial interests in research as well as exploring
systematically the nature of non-financial COIs in research.
39. James M. Wilson, Lessons Learned from the Gene Therapy Trial for
Ornithine Transcarbamylase Deficiency, 96 MOLECULAR GENETICS & METABOLISM 151, 152,
156 (2009).
40. Martha Ann Carey & Janice Swanson, Funding for Qualitative Research,
13 QUALITATIVE HEALTH RES. 852, 852 (2003).
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